Percepta: Interpreting hERG inhibition and cardiotoxicity alerts

Description
Some Percepta ADME/Tox modules predict potential hERG channel inhibition or cardiotoxicity risk based on structural features and data‑driven models. These predictions are screening tools and not definitive safety assessments.

Solution

1. Run the relevant cardiotoxicity or hERG‑related prediction modules in Percepta.
2. Review outcomes:
   • hERG Inhibition potency IC50.
   • hERG inhibitor Probability (Ki < 10 µM, patch-clamp)
3. Do not treat predictions as conclusive proof of safety or risk:
   • Use them to prioritize compounds for in vitro hERG or cardiotoxicity testing.
4. For compounds flagged as higher risk:
   • Consider structural modifications to reduce similarity to known risk motifs.
   • Plan targeted experimental assays (e.g., patch‑clamp, hERG binding).
5. Document use of these predictions as part of early risk assessment, supplemented by experimental data as development progresses.